CN204550582U - The device of tumour cell in a kind of separating blood fluid - Google Patents
The device of tumour cell in a kind of separating blood fluid Download PDFInfo
- Publication number
- CN204550582U CN204550582U CN201520192510.3U CN201520192510U CN204550582U CN 204550582 U CN204550582 U CN 204550582U CN 201520192510 U CN201520192510 U CN 201520192510U CN 204550582 U CN204550582 U CN 204550582U
- Authority
- CN
- China
- Prior art keywords
- freezing
- column
- pump
- separator column
- inlet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008280 blood Substances 0.000 title claims abstract description 49
- 210000004369 blood Anatomy 0.000 title claims abstract description 48
- 239000012530 fluid Substances 0.000 title claims abstract description 44
- 210000004881 tumor cell Anatomy 0.000 title claims abstract description 26
- 210000004027 cell Anatomy 0.000 claims abstract description 75
- 238000007710 freezing Methods 0.000 claims abstract description 47
- 239000005557 antagonist Substances 0.000 claims abstract description 28
- 239000002504 physiological saline solution Substances 0.000 claims abstract description 26
- 238000001914 filtration Methods 0.000 claims abstract description 22
- 230000002572 peristaltic effect Effects 0.000 claims abstract description 15
- 230000004087 circulation Effects 0.000 claims abstract description 10
- 239000007788 liquid Substances 0.000 claims description 53
- 238000012360 testing method Methods 0.000 claims description 22
- 230000001413 cellular effect Effects 0.000 claims description 19
- 238000000926 separation method Methods 0.000 claims description 19
- 239000007924 injection Substances 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 11
- 125000002015 acyclic group Chemical group 0.000 claims description 3
- 230000002337 anti-port Effects 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 description 40
- 201000011510 cancer Diseases 0.000 description 37
- 241001465754 Metazoa Species 0.000 description 26
- 238000000034 method Methods 0.000 description 15
- 230000008569 process Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000002785 anti-thrombosis Effects 0.000 description 5
- 229960004676 antithrombotic agent Drugs 0.000 description 5
- 239000012528 membrane Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000010586 diagram Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The utility model provides the device of tumour cell in a kind of separating blood fluid, comprise and being connected successively and the flow injecting mouth of energy circulation, the first driving pump, separator column and fluid outlet by major cycle pipeline, described first driving pump is peristaltic pump, and on described major cycle pipeline, be also provided with anti-freezing physiological saline inlet and anti-freezing antagonist inlet; Plural sub-Filter column is provided with in described separator column, and the trace-etching-film every sub-Filter column is provided with for separating of tumour cell, the aperture of described trace-etching-film is 5-25um, and the trace-etching-film in every sub-Filter column forms independently three-dimensional filtration channel; Described device also comprises cell harvestor; Described device successively forms filtration and departs from two operation paths.Described device is the omission utility model of a utility model patent in prior art.Device of the present utility model can realize its repertoire.
Description
Technical field
The utility model relates to cellular segregation field in fluid, is specifically related to the device of tumour cell in a kind of separating blood fluid.
Background technology
In prior art, at needs separation and detection living animal (comprising human body) cancer cells in blood (circulating tumorcells, CTC), time, be by extracting a certain amount of blood mostly, then carry out cell sorting and counting through methods such as density gradient centrifugations.Density gradient centrifugation in centrifuge tube, forms a continuous or discrete density gradient with certain medium, cell suspension or homogenate is placed in the top of medium, makes cell sorting by the effect of gravity or centrifuge field.But its shortcoming is obvious.Therefore, this area needs a kind of new apparatus and method for separating of the number with detection living animal cancer cells in blood.In recent years, there is the method by using trace-etching-film to carry out cancer cells in separating blood in this area, such as Cui washes and openly to use in the people such as China, Wang Shicheng disclosed " Synthesis and applications of polycarbonate track millipore filtration " track millipore filtration to diagnose cancer cells in blood, specifically the cancer cells be trapped on track millipore filtration is put into basis of microscopic observation.Contriver of the present utility model also uses this film to the cancer cells in the blood being separated some living animal (as bunny) and people and diagnoses this cancer cells and count.But device corresponding to such method only can cancer cells in the few part blood of flash liberation living animal, and can not the cancer cells in the major part of living animal or whole blood be effectively separated, especially for the living animal (as human body) that individuality is larger, this defect seems particularly outstanding.Reason is, the systemic blood of living animal can not be given out light be separated wherein cancer cells under being in normal existence state in order to keep animal, and a cognition is dead like this.In addition, because tumour cell (CTC) quantity in blood is very rare, if a small amount of blood only extracting living animal carries out separation detection, the susceptibility of its separation detection can reduce greatly; And increase processing blood amount, be all threaten to the health and lives of living animal.
Therefore, a kind of Fluid film filter cell separation device (as shown in the utility model accompanying drawing 5) is provided in the granted patent CN201410016566.3 of contriver's earlier application of the present utility model, comprise the first driving pump (1), the second driving pump (2), separator column (3), test column (4) and several T-valve and secondary driving pump, described secondary driving pump comprises the first auxiliary pump (11) and the second auxiliary pump (12); One end of described separator column is connected with the first driving pump (1) by the first T-valve (5), the other end is connected with the second driving pump (2) by the second T-valve (6), and described test column (4) is connected with the 3rd porthole of the first T-valve (5); At least five root Filter columns in parallel are comprised in described separator column (3), described sub-Filter column comprises fixed support and is attached to the polycarbonate of fixed support bottom and side surrounding or the trace-etching-film (7) of polyester material, and track etching membrane pore size is 5-25 μm; Described test column (4) comprises two portions up and down of flexible connection, two-part outside all arranges the fluid passage mouth (8) adapted with pipeline, interior vacancy between two portions of sealing arranges the trace-etching-film (7) of one deck polycarbonate or polyester material, and the aperture of trace-etching-film is 5-25 μm; And the 3rd T-valve (9) is set between the first driving pump (1) and the first T-valve (5), another passage of described 3rd T-valve is connected with driving first auxiliary pump (11) of anti-freezing physiological saline, and the 4th T-valve (10) is set between the second T-valve (6) and outlet (21), described 4th T-valve is connected with driving second auxiliary pump (12) of anti-freezing antagonist; Described device utilizes T-valve, separator column and test column to form two operation paths; Wherein, Article 1, path is that the cell suspension of large sample amount enters separator column (3) from cellular liquid container (18) then flow out from the other end through injection port (20), the first driving pump (1), the first T-valve (5), cellular liquid container (18) is got back to by outlet (21) again after filtering, be separated by the continuous circulation of cellular liquid container-pump-separator column, reach the object of the specific large volume cell of high efficiency separation; Article 2 path is adjustment first T-valve (5) and the second T-valve (6), close the connecting passage of injection port (20) and separator column (3), fluid flows counterflow through separator column (3) from the second driving pump (2) and then flows out from the other end, enter test column (4), this path carries out enrichment further to the specific large volume cell that separator column (3) is retained down, concentrated on the filtering membrane of test column (4), to carry out every downstream process detection to cell on film, waste liquid flows out from the other end of test column (4).
But contriver of the present utility model finds that in research subsequently this device still has deficiency, those skilled in the art still need to make efforts in this device of improvement.
Utility model content
Therefore, the utility model provides the device of tumour cell in a kind of separating blood fluid, comprise and being connected successively and the flow injecting mouth of energy circulation, the first driving pump, separator column and fluid outlet by major cycle pipeline, described first driving pump is peristaltic pump, and major cycle pipeline between described injection port and separator column is also provided with anti-freezing physiological saline inlet, and major cycle pipeline between described separator column and outlet is also provided with anti-freezing antagonist inlet;
Major cycle pipeline between described anti-freezing antagonist inlet and described separator column is the closed conduct without any sidewall opening, and the major cycle pipeline between described anti-freezing antagonist inlet and described outlet is also the closed conduct without any sidewall opening; Plural sub-Filter column is provided with in described separator column, and the trace-etching-film every sub-Filter column is provided with for separating of tumour cell, the aperture of described trace-etching-film is 5-25um, and the trace-etching-film in every sub-Filter column forms independently three-dimensional filtration channel; Described device also comprises cell harvestor;
Described device successively forms two operation paths; Wherein, Article 1, path is that blood enters separator column from cellular liquid container then flow out from its other end through injection port, the first driving pump, cellular liquid container is got back to again by outlet, carry out filtering separation by the continuous circulation of cellular liquid container-pump-separator column, reach the object of tumour cell in high efficiency separation blood; To major cycle pipeline, inject anti-freezing physiological saline and anti-freezing antagonist from described anti-freezing physiological saline inlet and described anti-freezing antagonist inlet respectively simultaneously; Article 2 path is the acyclic path contrary with Article 1 flow channels direction, wherein, second liquid stream injects major cycle pipeline from described outlet and/or described anti-freezing antagonist inlet, and the second liquid stream flows through described separator column and flow to the cell harvestor in the separator column downstream be arranged on the second fluid flow direction.
The aperture of the trace-etching-film 7 that the utility model provides is mated with the size of cancer cells to be separated, normal red corpuscle, white corpuscle and thrombocyte and other small molecules in blood all can normally be filtered, and cancer cells is trapped in the upstream side of trace-etching-film 7.In the utility model, described trace-etching-film 7 can be arranged on support bracket fastened outside, inner side or in the bracket embedding, unrestricted to this in the utility model.In the utility model, described separator column 3 and test column 42 all can freely horizontal positioned or vertically place or otherwise place, and all do not affect enforcement of the present utility model.
In the utility model, trace-etching-film in every sub-Filter column forms independently three-dimensional filtration channel and refers to that the trace-etching-film in sub-Filter column is not individual plane trace-etching-film, neither by the same direction of fluid flow multiple parallel plane trace-etching-films of process.In the utility model, form the filtration channel of (or jointly forming with membrane support) sub-Filter column towards the track etching membrane closure that different directions is arranged.In the utility model, described trace-etching-film can form cylindrical fluid passage, also can form cube shaped fluid channel.Parallel two maximized surfaces relatively of the sub-Filter column of such as sheet close trace-etching-film (flow is different through the direction of these two trace-etching-films), and other several little surface uses plastic-enclosed, other five surfaces except inlet face form three-dimensional filtration channel.
In the utility model, certain section of major cycle pipeline is refer to access in this section of major cycle pipeline without any fluid flow conduit without any the closed conduct of sidewall opening supply fluid to flow into from here or flow out major cycle pipeline.
Those skilled in the art are accessible, and described anti-freezing physiological saline inlet 9 between flow injecting mouth 20 and described peristaltic pump 1, between described peristaltic pump 1 and separator column 3, can not affect enforcement of the present utility model yet.
In the utility model, can be the damping fluids such as PBS, TBS for oppositely going out the second liquid stream of the tumour cell be trapped on trace-etching-film, or isotonic solution physiological saline.
In a kind of specific embodiment, use the first driving pump antiport to drive described second flowing of liquid stream in Article 2 path, described cell harvestor is connected to the first driving pump downstream on the second fluid flow direction.
In another kind of specific embodiment, described device also comprises the first auxiliary pump being connected to major cycle pipeline by pipeline from described anti-freezing physiological saline inlet, and described first auxiliary pump is peristaltic pump; Use the first auxiliary pump to drive described second flowing of liquid stream in Article 2 path, described cell harvestor is connected to the first auxiliary pump downstream on the second fluid flow direction.
In another kind of specific embodiment, described device also comprises the second auxiliary pump being connected to major cycle pipeline by pipeline from described anti-freezing antagonist inlet, and described second auxiliary pump is peristaltic pump; Use the second auxiliary pump to drive described second flowing of liquid stream in Article 2 path, described cell harvestor is connected to the separator column downstream on the second fluid flow direction.
Those skilled in the art are accessible, first driving pump 1 at least drives blood flow circulating in Article 1 path, but when in Article 2 path, the motivating force of the second fluid flow is provided by described first driving pump 1, described first driving pump 1 must be can rotate forward and counter-rotational peristaltic pump.Described first auxiliary pump 11 and the second auxiliary pump 12 can be peristaltic pump or driving pump, whether this plays a role according to this pump and determines in Article 2 path operational process, if it provides motivating force for Article 2 path, then its inevitable choice peristaltic pump, and the first auxiliary pump 11 must be can rotate forward and counter-rotational peristaltic pump.
Preferably, the major cycle pipeline between described separator column and described anti-freezing physiological saline inlet is the closed conduct without any sidewall opening.
In a kind of specific embodiment, described cell harvestor is fluid collecting container or test column, and containing the trace-etching-film that plane is arranged in described test column, the tumor cell enrichment that described test column can will flow through in the second liquid stream after separator column.
The tumour cell oppositely gone out from separator column 3 and the second liquid stream (as based on physiological saline) are all collected by fluid collecting container 41 described in the utility model, then send into and centrifugally in centrifugal device obtain tumour cell.Centrifugally operated is herein different from the centrifugally operated to blood stoste in background technology, because to filter through the utility model device and liquid centrifugal that obtain after recoil is the very simple solid-liquid separation of component, even and centrifugally operated now also can complete quickly and easily for a large amount of liquid samples.
Comprise trace-etching-film in described test column 42, the main part of described second liquid stream can filter by it, simultaneously by the tumor cell enrichment wherein carried secretly the upstream side at its trace-etching-film.In the utility model, described test column 42 carries out the detection of tumour cell under directly can delivering to detecting instrument.That is, in the utility model, the essence of described " test column 42 " is meant to tumour cell separation and concentration post.
In a kind of embodiment of aforesaid method, described cellular liquid container 18 is living animal or human body, in Article 1 path, injection port 20 connects the artery of living animal or human body, outlet 21 is communicated with the vein of described living animal or human body, makes living animal or blood of human body under the effect of the utility model device, realize the removing of cancer cells filtering separation and can not return in its body again.
In the utility model, described " anti-freezing physiological saline " refers to the physiological saline containing antithrombotics, described antithrombotics is such as edta salt or Citric Acid (citric acid) salt etc., and " anti-freezing physiological saline " being added in major cycle pipeline can not blood coagulation in the process that fluid (blood containing cancer cells) is contacted with described trace-etching-film 7 after entering separator column 3.Described " anti-freezing antagonist " refers to the physiological saline of the antagonist containing antithrombotics, and described " antagonist of antithrombotics " is calcium salt, as calcium chloride.Before the blood of filtering cancer cells has been sent back in living animal (containing human body) body, must adding described " anti-freezing antagonist " at the major cycle pipeline in separator column 3 downstream, the blood that with the addition of antithrombotics so just being made can not to produce toxic action because directly importing living animal to it.
After the circulation in device Article 1 path in the utility model, can circulate cancer cells in the blood making to reflux almost all or the overwhelming majority be removed, the liquid of bleeding that this device does not need to consume living animal or human body can reach the effect removing cancer cells in blood.So, after regularly using the cancer cells in the device filtering blood in the utility model, the transfer of cancer cells between blood is from a kind of organ of living animal or human body to other organ can be blocked.Especially in the scheme of the preferred separator column 3 containing many film pipes arranged side by side or multi-disc diaphragm (multiple sub-Filter column) arranged side by side, large-area trace-etching-film 7 makes the flux filtered significantly increase, and the fluid total volume that can meet in described cellular liquid container 18 is separated up to high efficiency filter time 5L (suitable with the total blood volume of human body).That is, device of the present utility model is that in the treatment of cancer metastasis and body, cancer cells reduces and provides a kind of ground-breaking novel method and new device, has high economic worth and social value.
In sum, realized the filtration of Article 1 path in earlier application by the driving (the first auxiliary pump 11 and the second auxiliary pump 12 are respectively used to inject anti-freezing physiological saline and anti-freezing antagonist in pipeline) of the first driving pump 1 simultaneously, the tumour cell realized in separator column 3 by the driving of the second driving pump 2 departs from from film the process entering the second liquid stream.
And in the utility model, eliminate the use of the second driving pump 2 and the pipeline with major cycle pipeline communication thereof, and utilize another driving pump (the first driving pump 1) that must exist in the utility model to drive the flowing of the second liquid stream, or (in first patent, the first auxiliary pump 11 and the second auxiliary pump 12 are the pump that must exist to utilize first auxiliary pump 11 that can exist and/or the second auxiliary pump 12, and the first auxiliary pump in the utility model and the second auxiliary pump are also necessary, but it can be equal to replacement by increasing pump head in parallel on the first driving pump 1) drive the flowing of the second liquid stream.
That is, present contriver finds, the second driving pump 2 departed from from separator column 3 for tumour cell in first patent is unnecessary existence, and when omitting this pump, device of the present utility model still can realize this detachment function.That is, the utility model compares immediate prior art, and after saving a wherein necessary key element, therefore the corresponding function of device does not disappear.Therefore, applicant proposes above-mentioned omitting elements utility model.
Use device of the present utility model, not only can be separated the cancer cells in living animal or body, directly reduce the cancer cell count circulated in blood, and then prevent the transfer of tumour between Different Organs; The utility model can also reach in the blood of diagnosis living animal or human body the object that whether there is cancer cells (whether cancer cells is transferred to blood from primary tumor) and detect cancer cells in blood number.
It will be appreciated by those skilled in the art that ground, above-mentionedly only illustrate the situation that in the utility model device, the installation of separator column 3 in Article 1 path and Article 2 path is not reversed end for end.In fact, when before startup Article 2 path, user is by the reversal connection of described separator column 3, and so still forward drive (identical with the peristaltic pump rotating manner in Article 1 path) the first driving pump 1 can realize the disengaging of cancer cells and described trace-etching-film 7 in separator column.Correspondingly, described cell harvestor (4) is connected in the downstream of separator column 3.
Use the method and apparatus in the utility model, not only achieve the detection to a large amount of cancer cells in blood number and counting.And directly the device in the utility model can also be communicated with the blood vessel of living animal or human body, thus realize the counting of total cancer cell count in the blood to living animal or human body when not extracting a living animal or blood of human body out.In addition, in the utility model the first driving pump effect under, corresponding can also realize remove cancer cells in blood, prevent cancer cells from the effect of primary tumor transfer of other organ in body.
Accompanying drawing explanation
The accompanying drawing forming a application's part is used to provide further understanding of the present utility model, and schematic description and description of the present utility model, for explaining the utility model, is not formed improper restriction of the present utility model.In the accompanying drawings:
Fig. 1 is the structural representation of the Article 1 path of the utility model preferred embodiment;
Fig. 2 is the structural representation of the Article 2 path of the utility model preferred embodiment;
Fig. 3 is the structural representation of the another kind of Article 2 path of the utility model preferred embodiment;
Fig. 4 is the structural representation of the another kind of Article 2 path of the utility model preferred embodiment;
Fig. 5 is the one-piece construction schematic diagram of the utility model device in first patent;
Fig. 6 is the comparison diagram of the device effect of device effect of the present utility model and traditional prior art.
1, the first driving pump, 2, the second driving pump, 3, separator column, 4, cell harvestor (test column), 41, fluid collecting container, 42, test column, the 5, first T-valve, 6, the second T-valve, 7, trace-etching-film, 8, fluid passage mouth, 9, anti-freezing physiological saline inlet (the 3rd T-valve), 10, anti-freezing antagonist inlet (the 4th T-valve), 11, the first auxiliary pump, the 12, second auxiliary pump, 18, cellular liquid container, 20, injection port, 21, outlet; Its bracket content is the tag content of the correspondence of the prior art of Fig. 5.
Embodiment
As provided the device of tumour cell in a kind of separating blood fluid in Fig. 1 and Fig. 2, comprise and being connected successively and the flow injecting mouth of energy circulation, the first driving pump, separator column and fluid outlet by major cycle pipeline, described first driving pump is peristaltic pump, and major cycle pipeline between described injection port and separator column is also provided with anti-freezing physiological saline inlet, and major cycle pipeline between described separator column and outlet is also provided with anti-freezing antagonist inlet; Major cycle pipeline between described anti-freezing antagonist inlet and described separator column is the closed conduct without any sidewall opening, and the major cycle pipeline between described anti-freezing antagonist inlet and described outlet is also the closed conduct without any sidewall opening; Be provided with plural sub-Filter column in described separator column, and every sub-Filter column is provided with the trace-etching-film for separating of tumour cell, the aperture of described trace-etching-film is 5-25um; Described device also comprises cell harvestor; Described device successively forms two operation paths; Wherein, Article 1, path (Fig. 1) enters separator column from cellular liquid container then flow out from its other end through injection port, the first driving pump for blood, cellular liquid container is got back to again by outlet, carry out filtering separation by the continuous circulation of cellular liquid container-pump-separator column, reach the object of tumour cell in high efficiency separation blood; To major cycle pipeline, inject anti-freezing physiological saline and anti-freezing antagonist from described anti-freezing physiological saline inlet and described anti-freezing antagonist inlet respectively simultaneously; Article 2 path (Fig. 2) is the acyclic path contrary with Article 1 flow channels direction, wherein, second liquid stream injects major cycle pipeline from described outlet and/or described anti-freezing antagonist inlet, and the second liquid stream flows through described separator column and flow to the cell harvestor in the separator column downstream be arranged on the second fluid flow direction.
Cellular liquid container 18 in Fig. 1 is human body or living animal, is the blood vessel in human body or living animal body from the pipeline of outlet 21 to cellular liquid container 18 with from the pipeline of cellular liquid container 18 to injection port 20.
Fig. 2 is that use first driving pump 1 and/or the second auxiliary pump 12 have driven described second flowing of liquid stream in Article 2 path, and described cell harvestor 4 is connected to the first driving pump 1 downstream on the second fluid flow direction.
Fig. 3 is that use first auxiliary pump 11 has driven described second flowing of liquid stream in Article 2 path, and described cell harvestor 4 is connected to the first auxiliary pump 11 downstream on the second fluid flow direction.The short tube being arranged in cell harvestor 4 left side in Fig. 3 represents can inject anti-freezing physiological saline from here at Article 1 path.That is, Article 1 path and Article 2 path device used can all be integrated in same equipment certainly.
Fig. 4 is the device fluid collecting container 41 in Fig. 2 being changed into test column 42, after the second liquid stream in the diagram in Article 2 path completes flow process, take off under described test column 42 can send into proofing unit (as microscope) and detect, and no longer need to carry out centrifugal acquisition tumour cell to the fluid in fluid collecting container 41.
See Fig. 6, the separating resulting utilizing the utility model device and conventional separation devices to carry out experiment in vitro compares.
First configure each 1000 of A549, LLC, H520, H1299 tetra-kinds of lung carcinoma cells respectively and jointly form 5L cell suspending liquid with physiological saline.
In device of the present utility model, the diameter of separator column is 6 centimetres, and grow 11 centimetres, it is 1 centimetre that 11 diameters are housed in separator column, the cylindrical filter post excessively arranged side by side of long 10 centimetres.Total effective filtration area of described separator column is 354 square centimeters.Cell suspending liquid circulates on separator column, and the cell suspending liquid total amount of this separator column process is 5L, and rate of flow of fluid is 250 ml/min.
Conventional separation devices, the shape of its separator column and the similar test column 4 in the utility model, its diameter is the effective filtration area of the trace-etching-film of 6 centimetres is 28.26 square centimeters.Cell suspending liquid is once property filtration on separator column, instead of circulates, and the above-mentioned cell suspending liquid total amount of this separator column process is 5mL.Therefore, in theory in this cell suspending liquid only containing about 1 cell.
In Fig. 6, solid dot represents the utility model device acquired results, and hollow dots represents conventional separation devices acquired results.As we can see from the figure, the number of complete, unabroken A549, LLC, H520, H1299 tetra-kinds of lung carcinoma cells that the utility model device is sorted into is respectively 988.33 ± 148.17,862.67 ± 103.65,1048 ± 79.3,855 ± 91.39.The result data configured in 1000 cells and Fig. 6 used in cell suspending liquid is all obtained by cell counter, therefore has a little error.And the separating for several times result of conventional separation devices can fluctuate at theoretical value (1 cancer cells); The data obtained like this cannot be used for the number of existence or the cancer cells in blood accurately judging whether to have cancer cells in the blood in living animal (comprising human body) body.
Device of the present utility model when omission second driving pump 2 and corresponding pipeline thereof, can realize with in the equal function of first patent CN201410016566.3.
The size of cancer cells is larger than the volume of normal plasma cell, even if may have part cancer cells in the utility model device through this film in the process of blood once-through separator column, also may have few part-blood cell retention on film; But because the separating step circulation of the device in the utility model is carried out, thus after blood repeatedly flows through separator column, film will be very thorough to the separation between normal plasma cell and cancer cells.
The foregoing is only preferred embodiment of the present utility model, be not limited to the utility model, for a person skilled in the art, the utility model can have various modifications and variations.All within spirit of the present utility model and principle, any amendment done, equivalent replacement, improvement etc., all should be included within protection domain of the present utility model.
Claims (6)
1. the device of tumour cell in a separating blood fluid, comprise and being connected successively and the flow injecting mouth (20) of energy circulation by major cycle pipeline, first driving pump (1), separator column (3) and fluid outlet (21), described first driving pump (1) is peristaltic pump, and major cycle pipeline between described injection port (20) and separator column (3) is also provided with anti-freezing physiological saline inlet (9), and major cycle pipeline between described separator column (3) and outlet (21) is also provided with anti-freezing antagonist inlet (10),
Major cycle pipeline between described anti-freezing antagonist inlet (10) and described separator column (3) is the closed conduct without any sidewall opening, and the major cycle pipeline between described anti-freezing antagonist inlet (10) and described outlet (21) is also the closed conduct without any sidewall opening; Plural sub-Filter column is provided with in described separator column (3), and the trace-etching-film (7) every sub-Filter column is provided with for separating of tumour cell, the aperture of described trace-etching-film is 5-25um, and the trace-etching-film (7) in every sub-Filter column forms independently three-dimensional filtration channel; Described device also comprises cell harvestor (4);
Described device successively forms two operation paths; Wherein, Article 1, path is that blood enters separator column (3) from cellular liquid container (18) then flow out from its other end through injection port (20), the first driving pump (1), cellular liquid container (18) is got back to again by outlet (21), carry out filtering separation by the continuous circulation of cellular liquid container-pump-separator column, reach the object of tumour cell in high efficiency separation blood; To major cycle pipeline, inject anti-freezing physiological saline and anti-freezing antagonist from described anti-freezing physiological saline inlet (9) and described anti-freezing antagonist inlet (10) respectively simultaneously; Article 2 path is the acyclic path contrary with Article 1 flow channels direction, wherein, second liquid stream injects major cycle pipeline from described outlet (21) and/or described anti-freezing antagonist inlet (10), and the second liquid stream flows through described separator column (3) and flow to the cell harvestor (4) in separator column (3) downstream be arranged on the second fluid flow direction.
2. device according to claim 1, it is characterized in that, use the first driving pump (1) antiport to drive described second flowing of liquid stream in Article 2 path, described cell harvestor (4) is connected to the first driving pump (1) downstream on the second fluid flow direction.
3. device according to claim 1, it is characterized in that, described device also comprises the first auxiliary pump (11) being connected to major cycle pipeline by pipeline from described anti-freezing physiological saline inlet (9), and described first auxiliary pump (11) is peristaltic pump; Use the first auxiliary pump (11) to drive described second flowing of liquid stream in Article 2 path, described cell harvestor (4) is connected to the first auxiliary pump (11) downstream on the second fluid flow direction.
4. device according to claim 1, it is characterized in that, described device also comprises the second auxiliary pump (12) being connected to major cycle pipeline by pipeline from described anti-freezing antagonist inlet (10), and described second auxiliary pump (12) is peristaltic pump; Use the second auxiliary pump (12) to drive described second flowing of liquid stream in Article 2 path, described cell harvestor (4) is connected to separator column (3) downstream on the second fluid flow direction.
5. according to device described in any one in Claims 1 to 4, it is characterized in that, the major cycle pipeline between described separator column (3) and described anti-freezing physiological saline inlet (9) is the closed conduct without any sidewall opening.
6. according to device described in any one in Claims 1 to 4, it is characterized in that, described cell harvestor (4) is fluid collecting container (41) or test column (42), and containing the trace-etching-film (7) that plane is arranged in described test column, the tumor cell enrichment that described test column (42) can will flow through in the second liquid stream after separator column (3).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201520192510.3U CN204550582U (en) | 2015-04-01 | 2015-04-01 | The device of tumour cell in a kind of separating blood fluid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201520192510.3U CN204550582U (en) | 2015-04-01 | 2015-04-01 | The device of tumour cell in a kind of separating blood fluid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN204550582U true CN204550582U (en) | 2015-08-12 |
Family
ID=53825718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201520192510.3U Expired - Fee Related CN204550582U (en) | 2015-04-01 | 2015-04-01 | The device of tumour cell in a kind of separating blood fluid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN204550582U (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104711188A (en) * | 2015-04-01 | 2015-06-17 | 刘韬 | Device for separating tumor cells in blood fluid |
| CN105126239A (en) * | 2015-10-09 | 2015-12-09 | 阚士锋 | Intelligent tumor treatment device |
-
2015
- 2015-04-01 CN CN201520192510.3U patent/CN204550582U/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104711188A (en) * | 2015-04-01 | 2015-06-17 | 刘韬 | Device for separating tumor cells in blood fluid |
| CN105126239A (en) * | 2015-10-09 | 2015-12-09 | 阚士锋 | Intelligent tumor treatment device |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104711188A (en) | Device for separating tumor cells in blood fluid | |
| WO2016112501A1 (en) | Device for separating cell in fluid | |
| MX2014006779A (en) | Method and device for sample processing. | |
| BR112014029935B1 (en) | centrifugal filtration device and cell sorting system with the same | |
| IT8967853A1 (en) | EQUIPMENT FOR THE TREATMENT OF CELLS | |
| CN104111190A (en) | Double-screw micro-fluidic chip | |
| CN204550582U (en) | The device of tumour cell in a kind of separating blood fluid | |
| CN102695804A (en) | Methods and apparatus for segregation of particles, including segregation and proliferation of fetal and stem cells | |
| CN106754344B (en) | The combined sorting purification devices and sorting detection method of circulating tumour cell | |
| JP6371857B2 (en) | Particle filtration apparatus and particle filtration method | |
| WO2020220684A1 (en) | In-vivo closed-loop extraction device for circulating tumor cells | |
| US20190151861A1 (en) | Method and apparatus for continuous removal of sub-micron sized particles in a closed loop liquid flow system | |
| CN107142202B (en) | A kind of cell extraction separation method that multifunction automatic biological cell is extracted separation control device and realized using the device | |
| CN109012207B (en) | Cross flow filtration system for enriching circulating tumor cells | |
| CN105505760B (en) | The full-automatic non-closed cell washing system of centrifugation | |
| CN103131693B (en) | Separation method of rare cells in blood | |
| CN206570309U (en) | A kind of circulating tumor cell sorts enriching apparatus | |
| CN108660060A (en) | It is a kind of enrichment, purification cycle tumour cell micro-fluidic chip | |
| CN106267407A (en) | Female tire Rh blood group incompatibility blood purifying therapeutical instrument | |
| CN203754717U (en) | Cell separation device adopting fluid film filtering | |
| CN109234152A (en) | A kind of circulating tumor cell separator | |
| CN208791620U (en) | It is a kind of enrichment, purification cycle tumour cell micro-fluidic chip | |
| CN106512121A (en) | Method and filtering device for removing AIDS viruses | |
| JP2004236527A (en) | Nucleated cell-separating device | |
| CN113444630A (en) | Automatic control system for filtering and separating circulating tumor cells by using porous filter membrane micro-fluidic chip |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160627 Address after: 410007 Hunan province Changsha Yuhua District, South Road No. 232 building 302 room 4 Jin Fu Yuan Patentee after: THE HUNAN CYCLE FILTER MEDICAL TECHNOLOGY Co.,Ltd. Address before: 410002 Hunan province Changsha Tianxin District Xiangfu Road No. 229 building East Building 402 room 4 Patentee before: Liu Tao |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150812 |